New test could transform diagnosis and treatment of STIs
A new rapid test for sexually transmitted infections could soon transform on-the-spot diagnosis and treatment.
Birmingham-based Linear Diagnostics has secured £1 million in funding to develop the technology, which could deliver results in less than 20 minutes.
The funding comes from the NIHR Invention for Innovation programme and will support a three-year project to finalise the test and prepare it for clinical trials.
Dr Jean-Louis Duprey, head of research and development at Linear Diagnostics, said: "We are developing a near patient device that will overcome this conundrum."
The company is working with the NIHR HealthTech Research Centre and the North East Innovation Lab to deliver the project.
Dr Jana Suklan, senior methodologist at the HRC, said: "The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology.
"Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology."
The test uses Linear's Exponential Amplification (EXPAR) technology, which detects bacterial DNA within minutes.
The company has focused on STIs such as Neisseria gonorrhoeae and Chlamydia trachomatis, where rapid diagnosis is essential to prevent further transmission and begin treatment immediately.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Organic Payment Gateways' CEO Highlights Demand for Webflow Healthcare Payment Integrations
SCARBOROUGH, Maine, June 10, 2025 /PRNewswire/ -- Alex Roy, CEO of Organic Payment Gateways, a leader in specialized payment solutions, today announced the launch of a new, tailored payment processing service designed specifically for healthcare practices built on the Webflow platform. This innovative offering directly addresses the significant challenges faced by healthcare providers, online pharmacies, and telemedicine service providers who have experienced payment rejections or declines from traditional processors such as Square, Stripe, or PayPal. The initiative responds to the increasing adoption of Webflow within the telehealth industry, providing a much-needed, reliable avenue for credit card transactions. Healthcare businesses often navigate a complex landscape when it comes to payment acceptance. The nature of their services, which can include prescriptions and virtual consultations, sometimes leads to their designation as "high-risk" by mainstream payment providers. This can result in frequent transaction declines, disruption of operations, and impacts on revenue stability. Organic Payment Gateways' new service is engineered to overcome these hurdles, ensuring that Webflow-based online healthcare entities can process credit card payments seamlessly and securely, fostering uninterrupted service delivery and consistent cash flow. The new service is built for the Webflow ecosystem, recognizing the platform's growing prominence in the digital health sector. It delivers a stable merchant account and payment gateway solution, featuring a critical, tested third-party integration with This integration provides a secure and versatile environment for processing payments using Webflow – especially for medical practices and online pharmacies that have been shut down by mainstream payment gateways like Stripe, Square, or PayPal. Alex Roy, CEO of Organic Payment Gateways, emphasized the company's interest in supporting this vital sector. "We've been listening to healthcare providers, online pharmacies, and telemedicine services – and more and more I hear about folks moving toward Webflow," Alex Roy stated. "It's clear that many are labeled high-risk and therefore struggling with payment processing, often getting flagged or shut down by the big names. I saw a real need there, and we're stepping up to make sure these essential businesses can focus on patient care, not payment gateway headaches." Alex Roy further highlighted the company's dedication to its clients. "Our approach has always been about genuine, one-on-one support. We're not just selling a service; we're building partnerships. We understand that every dollar counts for these businesses, which is why we're committed to offering a cost-effective solution, utilizing specifically underwritten health and pharmacy merchant accounts, payment software, and a tested, reliable third-party tool to ensure all the pieces work consistently and smoothly." Organic Payment Gateways' dedication to customer service is reflected in its 24/7 availability and its A+ rating from the Better Business Bureau, where it has been an accredited business since January 19, 2018. Organic Payment Gateways' BBB accreditation and reviews can be viewed at and additional customer feedback is available on Trustpilot at Healthcare providers interested in learning more about Organic Payment Gateways' Webflow-specific payment solutions can access comprehensive information at For a complete overview of payment processing options across the healthcare sector, visit About Organic Payment Gateways: Organic Payment Gateways is a leading provider of specialized credit card processing, merchant accounts, and payment gateway solutions. With a focus on industries often deemed high-risk or challenging by conventional processors, the company is dedicated to delivering reliable, secure, and affordable payment solutions tailored to the unique needs of its diverse clientele. Organic Payment Gateways prides itself on its personalized, USA-based customer service and commitment to fostering long-term business success. Learn more at Media Contact: Alex Roy 800-570-1347 396438@ View original content to download multimedia: SOURCE Organic Payment Gateways Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Avant Technologies Signs Letter of Intent for a Business Combination
LAS VEGAS, June 10, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced that it has entered into a non-binding letter of intent ("LOI") for a potential business combination with Ainnova Tech, Inc. (Ainnova). Ainnova, the Company's joint venture partner, is a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI). Ainnova's technology portfolio includes its cutting-edge AI-powered platform technology, Vision AI, several key algorithms, and its proprietary automated retinal camera, which is currently in development. Under the terms of the LOI, Avant and Ainnova would become a combined entity, with Ainnova rolling 100% of its outstanding equity and equity equivalents—or all its business—into the combined public company, with the deal structure to be determined later by the parties based on further due diligence findings and other considerations. Avant and Ainnova expect to announce additional details regarding the business combination when a definitive agreement is executed, which is expected in late June or early next quarter. Any transaction would be subject to board and equity holder approval of both companies, regulatory approvals, and other customary conditions. Avant and Ainnova executives believe that now is the time to strengthen their partnership and merge into a single entity before the Company's pre-submission meeting with the U.S. Food and Drug Administration in early July, in preparation for the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy. In late 2024, the two companies formed Ai-nova Acquisition Corp. (AAC) to advance and commercialize Ainnova's technology portfolio. During that time, the two companies completed further due diligence and focused on an opportunity to work together as one company. The Board of Directors and management team of Avant remain fully committed to executing the Company's strategic plan, which is focused on enhancing long-term value. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., said of the business combination, "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI—our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Video: Contact: Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc. View original content to download multimedia:
Yahoo
an hour ago
- Yahoo
L'Oréal to acquire majority stake in British skincare brand Medik8
L'Oréal Group has signed an agreement to acquire a majority stake in UK-based skincare brand Medik8. Inflexion, a European mid-market private equity company, will retain a minority share post-transaction. The acquisition is a strategic move by L'Oréal to bolster its Luxe division with a brand that has a strong foundation in scientific research and innovation. Medik8's performance and potential for international expansion make it a valuable addition to L'Oréal's portfolio. L'Oréal will begin to consolidate Medik8's sales following the transaction's closure. The agreement grants L'Oréal rights to eventually acquire the remaining shares held by minority shareholders. L'Oréal LUXE president Cyril Chapuy stated: 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. 'We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.' Completion of the transaction is anticipated in the summer or early autumn of 2025, pending regulatory approvals. Founded by scientist Elliot Isaacs, Medik8 is known for its CSA Philosophy: Vitamin C plus Sunscreen by day, Vitamin A by night. Medik8's has expanded its omni-channel sales strategy to include major online and offline retailers in Europe and the US. Medik8 CEO Simon Coble stated: 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' "L'Oréal to acquire majority stake in British skincare brand Medik8" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
